Infections by gram-negative bacteria (GNB) are common in clinics, and cases of infection that develop into sepsis and subsequent endotoxic shock, with high mortality (over 100,000 deaths in the United States annually), have increased in recent decades. The increase can be attributed to an escalating number of patients who are undergoing cancer therapy, immunosuppressive therapy, invasive surgical procedures, and human immunodeficiency virus infection, who are at high risk for developing sepsis (5, 18, 23) . In addition, GNB lysis may excessively release endotoxin and cause endotoxemia during antibiotic therapy. Various novel sepsis therapies currently under development and evaluation in clinical trials, including anticoagulant therapy, neutralization of lipopolysaccharide (LPS), and cytokine therapies, have not progressed essentially (10, 19, 26, 30) .
Infections by gram-negative bacteria (GNB) are common in clinics, and cases of infection that develop into sepsis and subsequent endotoxic shock, with high mortality (over 100,000 deaths in the United States annually), have increased in recent decades. The increase can be attributed to an escalating number of patients who are undergoing cancer therapy, immunosuppressive therapy, invasive surgical procedures, and human immunodeficiency virus infection, who are at high risk for developing sepsis (5, 18, 23) . In addition, GNB lysis may excessively release endotoxin and cause endotoxemia during antibiotic therapy. Various novel sepsis therapies currently under development and evaluation in clinical trials, including anticoagulant therapy, neutralization of lipopolysaccharide (LPS), and cytokine therapies, have not progressed essentially (10, 19, 26, 30) .
Bactericidal/permeability-increasing protein (BPI) is a 55-to 60-kDa human neutrophil granule-associated defense molecule specific for gram-negative bacteria, which was found in 1978 (13, 33, 35) . BPI has the specific effect of neutralizing endotoxin and directly killing GNB, but has no adverse effect on eukaryotic cells. It was demonstrated that the N terminus of BPI is identical to natural BPI in its effect on LPS and GNB (12, 15, 25, 34) . Recent studies with animal models of sepsis and endotoxemia and clinical trials treating septic patients suggested that the recombinant N terminus of BPI (rBPI 21 ) was a promising therapeutic agent. However, rBPI 21 has relatively low efficacy and short halflife in vivo, administration of rBPI 21 in a large dosage is very expensive, and it is difficult to maintain an optimal therapeutic level (6, 11) . In addition, recombinant BPI 21 and conventional antibiotics are principally suited to the treatment of existing bacterial infection rather than prevention of high-risk patients from developing sepsis.
In order to prolong and improve the activity of recombinant BPI 21 for clinical therapy of GNB infection, we applied a strategy (CAP18-immunoglobulin [Ig] fusion protein) similar to that of Warren and colleagues (32) to design and express a recombinant chimeric BPI 23 -Fc␥1 protein that consisted of the functional N terminus (amino acid residues 1 to 199) of human BPI and the Fc segment of human IgG1 . It has been demonstrated that the chimeric BPI 23 -Fc␥1 protein has the effect of neutralizing endotoxin, directly killing GNB (including drug-resistant GNB), as well as mediating opsonization (2) . Based on our preliminary work, we have sought to develop a BPI 23 -Fc␥1 transgene-based modality and to evaluate its potential in preventing GNB infection of clinical high-risk patients and, accordingly, in reducing the mortality of sepsis caused by GNB. In this study, the chimeric BPI 23 -Fc␥1 gene was reconstructed within a recombinant adeno-associated virus serotype 2 (rAAV2) vector as rAAV2-BPI 23 -Fc␥1, and subsequently delivered and expressed both in vitro and in vivo. The protective efficacy of chimeric BPI 23 -Fc␥1 gene delivery mediated by AAV2 against lethal Escherichia coli infection in the gene-transferred mice was fully characterized.
MATERIALS AND METHODS
Construction and production of rAAV2-BPI 23 -Fc␥1. The BPI gene fragment encoding the signal peptide and the functional N terminus (amino acid residues 1 to 199) of human BPI, named BPI 23 , was generated by reverse transcription-PCR (RT-PCR) using the primers P1 (5Ј-CTGGTACCATGAGAGAGAACA TGGCCA-3Ј) and P2 (5Ј-GCAAGCTTCTATTTTGGTCATTACTGGCAG-3Ј) from the mRNA of HL-60 cell line (ATCC CCL-240; ATCC, Manassas, VA). The Fc␥1 gene fragment encoding the Fc fragment of human immunoglobulin G1 was generated by RT-PCR using the primers P3 (5Ј-GTAAGCTTCTACAT GCCCACCGTGCCCAG-3Ј) and P4 (5Ј-TCGTCGACGGATCCTTATTTACC CGGAGACAGGGAG-3Ј) from the mRNA of human peripheral blood lymphocytes derived from a healthy volunteer. BPI 23 and Fc␥1 DNA fragments were then digested with KpnI/HindIII and HindIII/SalI, respectively, and were then coligated into the KpnI/SalI sites of the pSNAV vector (AGTC Gene Technology Co. Ltd., Beijing, China) (38) , designated as the pSNAV-BPI 23 -Fc␥1 expression vector, in which the chimeric BPI 23 -Fc␥1 gene controlled by the cytomegalovirus (CMV) promoter and simian virus 40 (SV40) poly(A) was flanked by AAV serotype 2 inverted terminal repeats.
rAAV2-BPI 23 -Fc␥1 viruses were prepared by AGTC Gene Technology Co. Ltd., complying with the guidelines of SFDA and GMP facilities, according to the protocols described previously (36, 37) . Briefly, BHK-21 cells (ATCC CCL-10) were transfected with the pSNAV-BPI 23 -Fc␥1 plasmid DNA using Metafectene (Biontex Laboratories GmbH, Munich, Germany) and selected by G418. rAAV2-BPI 23 -Fc␥1 viruses were rescued and produced by infecting the G418-resistant BHK-21 clones containing a BPI 23 -Fc␥1 gene with recombinant HSV1-rc/⌬UL2 helper viruses (AGTC Gene Technology Co. Ltd.) (37) . The rAAV2-BPI 23 -Fc␥1 viruses were purified and diluted to the concentration of 1 ϫ 10 12 vector genomes (v.g.)/ml used for the study.
Verification and expression of rAAV2-BPI 23 Mouse models of gene transfer. Five-to 6-week-old female BALB/c mice (provided by the Laboratory Animal Centre of The Academy of Military Medical Sciences, Beijing, China) were used to develop mouse models of gene transfer by AAV2. rAAV2-BPI 23 -Fc␥1 gene-transferred mice were administered a 100-l injection containing 1 ϫ 10 11 v.g. of rAAV2-BPI 23 -Fc␥1 through the quadriceps muscles of the right hind leg; rAAV2-EGFP gene-transferred mice were administered a 100-l injection containing 1 ϫ 10 11 v.g. of rAAV2-enhanced green fluorescent protein (EGFP)-expressing virus (AGTC Gene Technology Co. Ltd.); phosphate-buffered saline (PBS)-treated control mice were administered a 100-l injection of PBS. All experiments with gene-transferred mice described below were performed at an interval of 2 weeks after these injections were administered.
MLD of endotoxin or E. coli to BALB/c mice. LPS (Sigma) was diluted to 9.0 g/ml, 7.5 g/ml, 6.0 g/ml, and 4.5 g/ml with PBS containing 60 mg/ml D-galactosamine (Sigma). One hundred microliters of the selected dose of LPS was intraperitioneally injected into four separate groups of mice. The minimal dose that caused mortality of 90 to 100% of mice within 48 h was determined as the minimal lethal dose (MLD) of LPS for BALB/c mice.
E. coli O111:B4 [CMCC (B) no. 44101-9; CMCC, Beijing, China] was diluted to 2.5 ϫ 10 5 , 5 ϫ 10 4 , 2.5 ϫ 10 4 , and 5 ϫ 10 3 CFU/0.5 ml with autoclaved PBS buffer containing 5% (wt/vol) dried yeast. A 0.5-ml portion of the selected dose of E. coli for each mouse was intraperitoneally injected into four separate groups of mice. The minimal dose that caused 90 to 100% mortality within 48 h was determined as the MLD of E. coli O111:B4 for BALB/c mice.
RT-PCR. mRNA was extracted from rAAV2-BPI 23 -Fc␥1-injected mouse muscles with the Oligotex direct mRNA kit (QIAGEN, Hilden, Germany). RT-PCR was performed according to the manufacturer's instruction for the Access RT-PCR system (Promega, Madison, WI) in order to detect BPI 23 -Fc␥1 gene expression at the mRNA level. The specific primers used in RT-PCR are P1 and P4, as described above.
Immunohistochemical and histopathological observation. The paraffin-embedded sections of the injected mouse muscles were prepared and analyzed by standard immunohistochemical staining with HRP-conjugated mouse anti-human IgG Fc (Zymed Laboratories, Inc., San Francisco, CA) and diaminobenzidine (DAB) (Boster Biotech, Wuhan, China).
The paraffin-embedded sections of the main tissues of liver, small intestine, spleen, and kidney at 24 h after lethal E. coli challenge were prepared and examined by standard hematoxylin and eosin (H&E) staining.
ELISA. A modified enzyme-linked immunosorbent assay (ELISA) was performed as follows to examine the secreted BPI 23 -Fc␥1 protein in mouse sera. One hundred microliters of serum from rAVV2-BPI 23 -Fc␥1 gene-transferred mice was fully absorbed by nitrocellulose membrane for 15 min, while 100 l of serum from rAVV2-EGFP gene-transferred mice and 100 l of serum from PBS control mice were used as controls. The nitrocellulose membranes were dried in air for 20 min and laid on naked microtiter plates; these were tested with a biotinylated antibody against human BPI according to the protocol of a human BPI ELISA kit (HyCult Biotechnology b.v., Uden, The Netherlands).
Proinflammatory cytokines, interleukin-1␤ (IL-1␤) and tumor necrosis factor alpha (TNF-␣) in serum samples were detected by ELISA according to the instructions of a kit from R&D Systems Inc., Minneapolis, MN.
LAL assay. Serum samples were diluted in pyrogen-free water and then tested according to the instructions of the Limulus amebocyte lysate (LAL) kit (Shyihua Corp., Shanghai, China).
Bacterial count assay. For the in vitro bacterial count assay, 100 l of serum or anticoagulated blood from rAAV2-BPI 23 -Fc␥1 gene-transferred mice or rAAV2-EGFP gene-transferred mice was mixed with 100 l of E. coli (1 ϫ 10 3 CFU/ml), incubated at room temperature for 15 min, and then plated on two LB agar plates. Bacterial counts were performed after overnight incubation at 37°C from three individual experiments.
For the in vivo bacterial count assay, after E. coli attack, serum samples and homogenated samples from spleens and livers were serially diluted for the bacterial count and then dilution samples were inoculated onto two LB agar plates and incubated at 37°C for 24 h. Clones were counted, and the average from two plates was calculated in order to determine the bacterial count.
Statistical analysis. Data are presented as means Ϯ standard deviation (SD). A chi-square test was performed for the survival rate comparison. Differences among groups were analyzed by an independent-samples t test. (␣ ϭ 0.05, two-sided). P values of Ͻ0.05 were considered statistically significant. 23 (Fig. 1) . The rAAV2-BPI 23 -Fc␥1 virus was purified and diluted to 1 ϫ 10 12 v.g./ml as used for the study.
RESULTS

Construction and verification of rAAV2-BPI
First, we verified the integrity of our vectors in vitro. About 60% confluent CHO-K1 (ATCC CCL-61) cells were infected with rAAV2-BPI 23 -Fc␥1 virus at various MOI and then cultured in serum-free medium for 48 h. Dot blot analysis demonstrated the presence of secreted BPI 23 -Fc␥1 protein in the conditioned medium in a virus load-dependent manner ( Fig.  2A) . Western blot analysis demonstrated the presence of a 48-kDa band in dithiothreitol (DTT)-deoxidized medium and a 96-kDa band in nondeoxidized medium, which matches the expected size of BPI 23 -Fc␥1 protein (Fig. 2B) . It also was found that the secreted BPI 23 -Fc␥1 protein in the conditioned medium of CHO-K1 cells infected by rAAV2-BPI 23 -Fc␥1 virus had high efficacy of killing GNB (including drug-resistant GNB), neutralizing endotoxin, and mediating opsonization in vitro as well as of protecting mice from lethal E. coli infection in vivo (data not shown).
BPI 23 -Fc␥1 expression in vivo. The injected muscles were examined by RT-PCR and immunohistochemical staining to identify target gene expression at mRNA and protein levels in rAAV2-BPI 23 -Fc␥1 gene-transferred mice 2 weeks after intramuscular administration. An expected 1.4-kb-size band was found by RT-PCR using the primers 5Ј-CTGGTACCATGAG AGAGAACATGGCCA-3Ј and 5Ј-TCGTCGACGGATCCTT ATTTACCCGGAGACAGGGAG-3Ј for rAAV2-BPI 23 -Fc␥1 gene-transferred mice.
DAB-positive staining was observed in rAAV2-BPI 23 -Fc␥1 gene-transferred mice, but not in rAAV2-EGFP gene-transferred mice and PBS control mice (Fig. 3) . Green fluorescence was observed in the sections of the injected muscle of rAAV2-EGFP gene-transferred control mice. The results indicated that the target gene was successfully expressed in the injected muscles of rAAV2-BPI 23 -Fc␥1 gene-transferred mice 2 weeks after injection.
Detection of secreted BPI 23 -Fc␥1 in serum. Serum samples were collected 2 weeks after administration of vector genomes. The following experiments were performed at the same time.
First, the serum was analyzed by a modified ELISA to detect the secreted BPI 23 Detection of BPI 23 -Fc␥1 protein activity in vitro. To assess the endotoxin-neutralizing activity of secreted BPI 23 -Fc␥1 protein in serum, 50 l serum was incubated with 50 l endotoxin solution (0.25 endotoxin units [EU]/ml) diluted with pyrogenfree water for 30 min at 37°C, and then the mixture was tested with the LAL assay. LPS standard in pyrogen-free water (0.125 EU/ml LPS standard) had an OD 545 of 0.320 Ϯ 0.03 (n ϭ 3). However, the same quantity of LPS in the dilution containing 50% rAAV2-EGFP control mouse serum had an OD 545 of 0.287 Ϯ 0.021 (n ϭ 3), which is lower than that of the standard. The result proved, as reported in the literature (16, 26, 28) , that some components (high-density lipoprotein; cathelicidin) in mouse serum are able to neutralize LPS. Nevertheless, the LPS sample containing serum from rAAV2-BPI 23 -Fc␥1 genetransferred mice had an OD 545 of 0.173 Ϯ 0.021(n ϭ 3), which is significantly lower than the value of 0.287 Ϯ 0.021(n ϭ 3) from the control group containing normal mouse serum. Thus, we believe that the target gene expression creates BPI 23 -Fc␥1 protein to neutralize LPS, although there are some nonspecific LPS-neutralizing activities in normal mouse serum.
Meanwhile, we also verified protection of mice from lethal endotoxin (LPS) attack as follows. First, we titrated the MLD of LPS (600 ng/mouse) for BALB/c mice. Then, the survival rate was observed within 48 h after lethal LPS challenge. The survival rate of rAAV2-BPI 23 -Fc␥1 gene-transferred mice (40%; n ϭ 20) was significantly higher than those of rAAV2-EGFP gene-transferred control mice (5%; n ϭ 20) and PBS control mice (0%; n ϭ 20) (20) . The results also suggested that the target product in rAAV2-BPI 23 -Fc␥1 gene-transferred mice could neutralize endotoxin (LPS) and protect mice from the challenge of lethal endotoxemia.
We further assessed the bactericidal activity and the opsonization effect of secreted BPI 23 -Fc␥1 in serum on E. coli O111:B4 [CMCC (B) no. 44101-9]. As shown in Table 1 , the bacterial counts from rAAV2-BPI 23 -Fc␥1 gene-transferred mice (21.33 Ϯ 2.08 and 13.67Ϯ3.06) were significantly lower than those from rAAV2-EGFP gene-transferred mice (33.33 Ϯ 4.93 and 34.67 Ϯ 5.51) either in serum (P ϭ 0.018) or in anticoagulated blood (P ϭ 0.002). The bacterial count from anticoagulated blood in rAAV2-BPI 23 -Fc␥1 gene-transferred mice (13.67 Ϯ 3.06) was significantly lower than that from serum in rAAV2-BPI 23 b One hundred microliters of 12.5, 25, 50, 100, or 200 g cefuroxime sodium was administered intramuscularly to groups of 10 BALB/c mice 1 h after challenge with the MLD of E. coli. The mortality of mice in the groups given 25 g cefuroxime sodium at 48 h was 91.4% (n ϭ 40). Twenty-five micrograms/100 l was finally defined as the minimal dose of cefuroxime sodium in experiments for synergism with antibiotics.
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BPI 23 -Fc␥1 GENE DELIVERY FOR PROTECTION FROM E. COLI 727 bacterial counts from serum and anticoagulated blood in the rAAV2-EGFP gene-transferred control mice (P ϭ 0.770). These results suggested that while the secreted chimeric BPI 23 -Fc␥1 protein alone could kill E. coli, the capacity to kill E. coli could be improved significantly in the presence of phagocytes; in contrast, phagocytes alone were unable to kill E. coli under the experimental conditions. Protection of mice from lethal E. coli infection. To titrate the MLD of E. coli O111:B4 for BALB/c mice, different doses of E. coli O111:B4 were administered intraperitoneally to four groups of BALB/c mice (n ϭ 10). The infected mice began to die 18 h after infection, and the mortality rates of the group injected with the doses of 2.5 ϫ 10 5 , 5 ϫ 10 4 , 2.5 ϫ 10 4 , and 5 ϫ 10 3 CFU/0.5 ml E. coli O111:B4 within 48 h were 100% (10/10), 100% (10/10), 92.5% Ϯ 5% (37/40), and 60%(10/10), respectively. Hereby, 2.5 ϫ 10 4 CFU/0.5 ml was determined to be the MLD of E. coli O111:B4 for BALB/c mice.
To prove protection of mice from challenge of lethal E. coli infection, BALB/c mice were attacked with an MLD of E. coli O111:B4 intraperitoneally 2 weeks after transfer with a 100-l injection containing 1 ϫ 10 11 v.g. of rAAV2-BPI 23 -Fc␥1 virus intramuscularly, while other mice were gene transferred with a 100-l injection containing 1 ϫ 10 11 v.g./100 l of rAAV2-EGFP virus or injected with 100 l PBS as controls. Then, the survival rates were observed within 48 h after infection with the MLD of E. coli, and reproducible results were obtained ( Table  2 ). The survival rate of rAAV2-BPI 23 -Fc␥1 gene-transferred mice (37.50%) was significantly higher than those of rAAV2-EGFP gene-transferred mice (2.50%) and PBS control mice (4.17%), while there was no statistically significant difference between the survival rates of rAAV2-EGFP gene-transferred control mice and PBS control mice. The results demonstrated that rAAV2-mediated BPI 23 -Fc␥1 gene transfer protected mice from the challenge of lethal E. coli O111:B4 infection.
Furthermore, data in Table 2 also show that the survival ratio of rAAV2-BPI 23 -Fc␥1 gene-transferred mice administered the minimal dose of antibiotic (25 g cefuroxime per mouse) was markedly increased to 67.50%. The survival ratios of the cefuroxime group and rAAV2-EGFP-cefuroxime group were 5.00% and 7.50%, respectively. This indicates the potential for cooperative use of rAAV2-mediated BPI 23 -Fc␥1 gene delivery and the minimal dose of antibiotics in the clinical scenario to improve the therapy of GNB infections.
Biological functions of secreted BPI 23 -Fc␥1 and resulting changes in vivo. To further evaluate the biological activity of secreted BPI 23 -Fc␥1 protein in rAAV2-BPI 23 -Fc␥1 genetransferred mice, the levels of bacterial count, endotoxin, and proinflammatory cytokines and histological alterations in vivo were measured after lethal E. coli challenge. First, blood samples from orbital bulb and main viscus were simultaneously collected at 6, 9, 12, and 24 h after the MLD of E. coli O111:B4 infection, and then the serum samples from the collected blood samples and the homogenated samples from the collected integrated spleens and livers were prepared. Each serum sample and homogenated sample was detected by bacterium-counting assay. It was shown that the counts of bacteria in the serum, spleen, and liver of rAAV2-BPI 23 -Fc␥1 gene-transferred mice were markedly lower than those for rAAV2-EGFP gene-transferred control mice (Fig. 5A , B, and C). The results demonstrated that the target product in rAAV2-BPI 23 -Fc␥1 genetransferred mice could kill E. coli and improve the resistance of mice against lethal E. coli infection. Second, blood samples were collected from orbital bulb at 6, 12, 18, and 24 h after the MLD of E. coli O111:B4 infection and serum samples of three mice from the same group were prepared and mixed together. Each 100 l of the mixed serum sample was detected by LAL assay for endotoxin and by ELISA for proinflammatory cytokines. The level of endotoxin in the serum of rAAV2-BPI 23 -Fc␥1 gene-transferred mice reached its peak at 12 h and was significantly lower than that of rAAV2-EGFP gene-transferred control mice, with a peak at 18 h (Fig. 6A) . Correspondingly, the levels of IL-1␤ and TNF-␣ in the serum of rAAV2-BPI 23 -Fc␥1 gene-transferred mice reached a peak at 12 h and was significantly lower than that of rAAV2-EGFP gene-transferred control mice, with a peak at 18 h after lethal E. coli infection (Fig. 6B and C) . It was obvious that the markedly increasing levels of endotoxin and proinflammatory cytokines in serum of rAAV2-EGFP-transferred control mice with a peak at 18 h were responsible for the death of the animals (mortality up to 92.5%) occurring 18 h after E. coli infection. The results suggested that rAAV2-BPI 23 -Fc␥1 gene-transferred mice could resist the endotoxic shock caused by lethal E. coli infection through killing E. coli, neutralizing endotoxin, and decreasing the level of proinflammatory cytokines.
In addition, the main viscus of the experimental mice, including liver, small intestine, spleen, and kidney was examined by standard H&E staining 24 h after challenge with lethal E. coli infection. In comparison, the main viscus of the surviving mice protected by rAAV2-BPI 23 -Fc␥1 gene transfer showed only a slight congestion, while the main viscus of the agonal mice from rAAV2-EGFP-transferred control mice showed significant pathological alterations, such as capillary dilatation and congestion, which were consistent with what endotoxic shock should show.
DISCUSSION
The viral delivery system has been widely used in gene therapy protocols for its high efficiency (3). A "gutless" viral vector is safer because there is less oncogenicity and less immunogenicity (7, 17) and is suitable for gene therapy of bacterial infections because it does not exaggerate the inflammatory reaction caused by infection. AAV vectors, a kind of gutless vector, are based upon a class of viruses that commonly inhabit a human host without causing any detectable pathology. In particular, AAV2 has been widely used as a gene delivery vehicle in preclinical studies and its use in early-phase clinical trials has been reported (8, 9) . AAV2-mediated gene delivery has a slow but long-term gene expression which reaches the peak at the 2nd to 3rd week and then persists more than several months after delivery (9, 14) . In this study, we produced rAAV2-BPI 23 -Fc␥1 virus with a high viral load that successfully mediated BPI 23 -Fc␥1 gene transfer and expression in mouse muscle cells (Fig. 3) : it was further secreted into blood circulation, suggesting that the AAV2-mediated BPI 23 -Fc␥1 gene delivery system may be suitable for administration to patients at high risk of infection.
By 2004, over 700 gene therapy/transfer protocols, which cover cancer, monogenic diseases, and viral infections, primarily peripheral and coronary artery diseases, but not bacterial infections, had been initiated worldwide (29) . The latest studies have shown that adenovirus-mediated fulllength BPI gene transfer could protect mice from endotoxemia but not from lethal E. coli infection (1). The half-life of recombinant BPI in vivo was determined to be less 45 min; however, BPI itself required 3 h or more to kill bacteria, which might explain why BPI alone was not able to protect BPI gene-transferred mice from lethal E. coli challenge. In comparison with BPI, chimeric BPI 23 -Fc␥1 protein not only had a longer half-life, but also accumulated in blood as it acted like immunoglobulin. The secreted BPI 23 -Fc␥1 protein in the serum of rAAV2-BPI 23 -Fc␥1 gene-transferred mice displayed the effects of neutralizing endotoxin, killing E. coli and mediating opsonization (Table 1 ). After challenge with lethal E. coli O111:B4 infection, the count of bacteria in serum and in main viscus, as well as the level of endotoxin and proinflammatory cytokines in serum of rAAV2-BPI 23 -Fc␥1 gene-transferred mice decreased (Fig. 5 and 6 ), and the survival rate of rAAV2-BPI 23 -Fc␥1 gene-transferred mice increased markedly, especially when combined with antibiotics (Table 2) , which was similar to the findings in previous studies on synergism of recombinant BPI and antibiotics (6, 11) , implying that the efficacy of anti-GNB infection could be maximized by delivering the BPI 23 -Fc␥1 gene and administering minimal amounts of antibiotics in patients. In addition, corresponding to the markedly increased levels of circulating endotoxin and proinflammatory cytokines, the rAAV2-EGFP control group mice had high mortality (above 90%) during lethal E. coli infection, and the agonal mice in the rAAV2-EGFP control group showed significant histological alterations, such as capillary dilation and congestion in the main viscus, which were consistent with the clinical finding of endotoxic shock.
The results of the experiment indicate AAV2-mediated BPI 23 -Fc␥1 gene delivery has potential for preventing clinical high-risk patients from being infected by GNB. In general, before reaching the MLD, the invading GNB in high-risk patients may be effectively eliminated by rAAV2-mediated BPI 23 -Fc␥1 gene transfer. In addition, compared with traditional antibiotics, BPI 23 -Fc␥1 protein has the advantages of neutralizing endotoxin that can protect host from endotoxemia and endotoxic shock and of killing drug-resistant GNB with dual pathways by BPI's direct killing and Fc␥1-mediated opsonization (11, 22) . These findings highlight how chimeric BPI 23 -Fc␥1 protein can induce LPS-anchored phagocytosis by phagocytes in order to kill GNB in vivo. With the success of the rAAV2-BPI 23 -Fc␥1 gene transfer modality against GNB infection in mice model, we believe that rAAV2-BPI 23 -Fc␥1 gene transfer can protect high-risk patients from serious GNB infection and sepsis. We also consider that BPI 23 -Fc␥1 gene delivery by double-stranded AAV vector or mini-adenovirus vector (4, 21, 24, 27, 31) , as well as other kinds of gutless vectors developed recently, can enable the therapeutic gene to be expressed more quickly and strongly than the single-stranded AAV vector, so it will have quick and strong effects against GNB infection and will show special potential for treatment and prophylaxis.
